PT  - JOURNAL ARTICLE
AU  - ELENA COJOCARU
AU  - KHIN THWAY
AU  - CYRIL FISHER
AU  - CHRISTINA MESSIOU
AU  - SHANE ZAIDI
AU  - AISHA B. MIAH
AU  - CHARLOTTE BENSON
AU  - SPYRIDON GENNATAS
AU  - PAUL HUANG
AU  - ROBIN L. JONES
TI  - Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue
AID  - 10.21873/anticanres.14725
DP  - 2020 Dec 01
TA  - Anticancer Research
PG  - 7003--7007
VI  - 40
IP  - 12
4099  - http://ar.iiarjournals.org/content/40/12/7003.short
4100  - http://ar.iiarjournals.org/content/40/12/7003.full
SO  - Anticancer Res2020 Dec 01; 40
AB  - Background/Aim: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma. Patients and Methods: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital. Results: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months. Conclusion: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease.